Visus Therapeutics

Visus Therapeutics is a clinical-stage pharmaceutical company that specializes in the development of unique and superior ophthalmic therapies. The company is primarily focused on improving the lives of patients by addressing the loss of near vision associated with presbyopia, a common age-related eye condition. Their lead clinical candidate is BRIMOCHOL™, an eye drop that is currently being evaluated for its effectiveness in treating presbyopia.

The company operates in the healthcare and pharmaceutical market, serving a broad range of clients including healthcare providers, patients, and other stakeholders in the healthcare industry. With offices in Seattle and Orange County, Visus Therapeutics is strategically positioned to serve its target market effectively.

Visus Therapeutics' business model revolves around the research, development, and commercialization of innovative ophthalmic therapies. The company generates revenue through the sale of its pharmaceutical products once they have been approved for use in the market. The recent positive topline clinical data from their Phase 3 BRIO-I Trial of BRIMOCHOL PF™ indicates that the company is making significant progress towards commercializing their lead product.

In August 2021, Visus Therapeutics hosted its first Capital Markets Day in New York City, a move that underscores the company's commitment to engaging with investors and the broader financial community.

Keywords: Visus Therapeutics, pharmaceutical, ophthalmic therapies, presbyopia, BRIMOCHOL™, healthcare market, clinical-stage, research and development, commercialization, Capital Markets Day.